Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Study connect Webseite durchsuchen

Active, Not Recruiting

An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread - CA209-142

Aktualisiert: 8 Mai, 2024   |

Ziehen Sie diese Studie in Erwägung?
Drucken Sie diese Seite und den Studienleitfaden zur Unterstützung Ihres Gesprächs mit dem Arzt.aus.
Verwenden Sie den Studienleitfaden, um den Prozess der Teilnahme an einer klinischen Studie zu überblicken. Verstehen Sie die wichtigsten zu berücksichtigenden Faktoren, bevor Sie sich entscheiden und Fragen an Ihr Gesundheitsteam stellen.


  • Phase 2


  • Geschlecht(er)

  • 18+


  • Active, Not Recruiting


Experimental: Nivolumab (Nivo) + BMS-986016 Cohort C5
Drug: anti-LAG-3 antibody, Nivolumab
Experimental: Nivolumab (Nivo) + Daratumumab Cohort C6
Drug: Daratumumab, Nivolumab
Experimental: Nivolumab (Nivo) + Ipilimumab (Ipi)
Drug: Nivolumab, Ipilimumab
Experimental: Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4
Drug: Ipilimumab, Cobimetinib, Nivolumab
Experimental: Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3
Drug: Nivolumab, Ipilimumab
Experimental: Nivolumab Monotherapy
Drug: Nivolumab

Wichtigste Eignungskriterien

For more information regarding BMS clinical trial participation, please visit Inclusion Criteria: - Men and women ≥ 18 years of age - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 - Histologically confirmed recurrent or metastatic colorectal cancer - Measurable disease by CT or MRI - Testing for MSI Status (by an accredited lab) 1. Subjects with microsatellite instability high (MSI-H) tumors will enroll in the MSI-H Cohort (mStage and cStage groups), the C3 Cohort, and the C5 Cohort. 2. Subjects with phenotypes that are non-microsatellite instability high (non-MSI-H) will enroll in the non- MSI-H Safety Cohort and the C6, C4 Cohorts. - Adequate organ function as defined by study-specific laboratory tests - Must use acceptable form of birth control throughout the study. After the final dose of study drug, an acceptable form of birth control must be used for 23 weeks for women of childbearing potential (WOCBP) and 31 weeks for men who are sexually active with WOCBP - Signed informed consent - Willing and able to comply with study procedures - Subjects enrolled into the C3 Cohort must have not had treatment for their metastatic disease Exclusion Criteria: - Active brain metastases or leptomeningeal metastases are not allowed. - Prior treatment with an anti-Programmed Death Receptor (PD)-1, anti-PD-L1, anti-PD-L2, anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways - Prior malignancy active within the previous 3 years except for locally curable cancers - Subjects with active, known or suspected autoimmune disease - Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration Other protocol defined inclusion/exclusion criteria could apply

Wir empfehlen Ihnen dringend, sich an Bristol Myers Squibb zu wenden, um Nebenwirkungen (unerwünschte Ereignisse) zu melden.
Nebenwirkungen (unerwünschte Ereignisse) und andere meldepflichtige Ereignisse werden hier definiert
Nebenwirkungen (unerwünschte Ereignisse) oder Produktqualitätsbeschwerden melden: Medizinische Information